231 related articles for article (PubMed ID: 32510599)
1. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A; Oñate G; Diaz-Beyá M; Guijarro F; Garrido A; Vives S; Tormo M; Arnan M; Salamero O; Sampol A; Coll R; Vall-Llovera F; Oliver-Caldés A; López-Guerra M; Pratcorona M; Zamora L; Villamon E; Roué G; Blanco A; Nomdedeu JF; Colomer D; Brunet S; Sierra J; Esteve J;
Br J Haematol; 2020 Oct; 191(1):52-61. PubMed ID: 32510599
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
3. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
[TBL] [Abstract][Full Text] [Related]
4. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
5. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer S; Weber D; Corbacioglu A; Gaidzik VI; Paschka P; Krönke J; Theis F; Rücker FG; Teleanu MV; Panina E; Jahn N; Herzig J; Kubanek L; Schrade A; Göhring G; Fiedler W; Kindler T; Schroeder T; Mayer KT; Lübbert M; Wattad M; Götze KS; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Krauter J; Bullinger L; Krzykalla J; Benner A; Schlenk RF; Thol F; Heuser M; Ganser A; Döhner H; Döhner K
Blood; 2020 Dec; 136(26):3041-3050. PubMed ID: 33367545
[TBL] [Abstract][Full Text] [Related]
6. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
7. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
8. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
9. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
10. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
[TBL] [Abstract][Full Text] [Related]
11. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
12. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.
Hubmann M; Köhnke T; Hoster E; Schneider S; Dufour A; Zellmeier E; Fiegl M; Braess J; Bohlander SK; Subklewe M; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Hiddemann W; Spiekermann K
Haematologica; 2014 Aug; 99(8):1317-25. PubMed ID: 24816240
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Guolo F; Minetto P; Clavio M; Miglino M; Colombo N; Cagnetta A; Cea M; Marcolin R; Todiere A; Ballerini F; Gobbi M; Lemoli RM
Br J Haematol; 2019 Sep; 186(6):e223-e225. PubMed ID: 31348524
[No Abstract] [Full Text] [Related]
16. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.
Tiong IS; Dillon R; Ivey A; Kuzich JA; Thiagarajah N; Sharplin KM; Kok CH; Tedjaseputra A; Rowland JP; Grove CS; Abro E; Shortt J; Hiwase DK; Bajel A; Potter NE; Smith ML; Hemmaway CJ; Thomas A; Gilkes AF; Russell NH; Wei AH
Blood Adv; 2021 Dec; 5(23):5107-5111. PubMed ID: 34555849
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS; Dillon R; Ivey A; Teh TC; Nguyen P; Cummings N; Taussig DC; Latif AL; Potter NE; Runglall M; Russell NH; Raj K; Schwarer AP; Fong CY; Grigg AP; Wei AH
Br J Haematol; 2021 Mar; 192(6):1026-1030. PubMed ID: 32458446
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia.
Gao MG; Ruan GR; Chang YJ; Liu YR; Qin YZ; Jiang Q; Jiang H; Huang XJ; Zhao XS
Ann Hematol; 2020 Jan; 99(1):73-82. PubMed ID: 31768677
[TBL] [Abstract][Full Text] [Related]
20. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Sartor C; Brunetti L; Audisio E; Cignetti A; Zannoni L; Cristiano G; Nanni J; Ciruolo R; Zingarelli F; Ottaviani E; Patuelli A; Bandini L; Forte D; Sciabolacci S; Cardinali V; Papayannidis C; Cavo M; Martelli MP; Curti A
Br J Haematol; 2023 Aug; 202(3):599-607. PubMed ID: 37226312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
